Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance

International Journal of Antimicrobial Agents

Volumn 42, Issue 1, 2013, Pages 80-82

  Van Ingen, Jakko ^a   Hoefsloot, Wouter ^a   Mouton, Johan W ^a   Boeree, Martin J ^a   Van Soolingen, Dick ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Ethambutol; Mycobacterium avium complex; Mycobacterium xenopi; Nontuberculous mycobacteria; Rifampicin; Synergy

Indexed keywords

ETHAMBUTOL; RIFAMPICIN;

ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; ATYPICAL MYCOBACTERIUM; BACTERIAL STRAIN; BACTERIUM ISOLATE; HUMAN; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM CHIMAERA; MYCOBACTERIUM INTRACELLULARE; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM MALMOENSE; MYCOBACTERIUM SIMIAE; MYCOBACTERIUM XENOPEI; PRIORITY JOURNAL;

ANTITUBERCULAR AGENTS; DRUG SYNERGISM; ETHAMBUTOL; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA; RIFAMPIN;

EID: 84879238307     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.03.010     Document Type: Article

References (15)

1. D.E. Griffith, T. Aksamit, B.A. Brown-Elliot, A. Catanzaro, C. Daley, and F. Gordin An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases Am J Respir Crit Care Med 175 2007 367 416
2. P.A. Jenkins, I.A. Campbell, J. Banks, C.M. Gelder, R.J. Prescott, and A.P. Smith Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy Thorax 63 2008 627 634
3. J. van Ingen, T. van der Laan, P.N.R. Dekhuijzen, M.J. Boeree, and D. van Soolingen In vitro drug susceptibility of 2275 clinical nontuberculous Mycobacterium isolates of 49 species in The Netherlands Int J Antimicrob Agents 35 2010 169 173
4. J. Banks, and P.A. Jenkins Combined versus single antituberculosis drugs on the in vitro sensitivity patterns of non-tuberculous mycobacteria Thorax 42 1987 838 842
5. S.E. Hoffner, N. Heurlin, B. Petrini, S.B. Svenson, and G. Kallenius Mycobacterium avium complex develops resistance to synergistically active drug combinations during infection Eur Respir J 7 1994 247 250
6. S.E. Hoffner, S.B. Svenson, and A.E. Beezer Microcalorimetric studies of the initial interaction between antimycobacterial drugs and Mycobacterium avium J Antimicrob Chemother 25 1990 353 359
7. I. Ben Salah, T. Adékambi, D. Raoult, and M. Drancourt rpoB sequence-based identification of Mycobacterium avium complex species Microbiology 154 2008 3715 3723
8. F.C. Odds Synergy, antagonism, and what the chequerboard puts between them J Antimicrob Chemother 52 2003 1
9. J. van Ingen, M. Boeree, D. van Soolingen, and J. Mouton Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria Drug Resist Updat 15 2012 149 161
10. J. van Ingen, E.F. Egelund, A. Levin, S.E. Totten, M.J. Boeree, and J.W. Mouton The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment Am J Respir Crit Care Med 186 2012 559 565
11. R. Jayaram, S. Gaonkar, P. Kaur, B.L. Suresh, B.N. Mahesh, and R. Jayashree Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis Antimicrob Agents Chemother 47 2003 2118 2124
12. D. Deshpande, S. Srivastava, C. Meek, R. Leff, and T. Gumbo Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium Antimicrob Agents Chemother 54 2010 1728 1733
13. J. van Ingen, S.E. Totten, L.B. Heifets, M.J. Boeree, and C.L. Daley Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease Int J Antimicrob Agents 39 2012 173 176
14. J. van Ingen, M.J. Boeree, D. van Soolingen, M.D. Iseman, L.B. Heifets, and C.L. Daley Are phylogenetic position, virulence, drug susceptibility and in vivo response to treatment in mycobacteria interrelated? Infect Gen Evol 12 2011 832 837
15. J. van Ingen, R.E. Aarnoutse, P.R. Donald, A.H. Diacon, R. Dawson, and G. Plemper van Balen Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin Infect Dis 52 2011 e194 e199